Analysts and investors found plenty to like in first quarter earnings from Regeneron Pharmaceuticals Inc., which beat consensus revenue forecasts with approximately $1.2 billion in global sales, including a 44 percent increase in U.S. and global net sales of Eylea (aflibercept).